Min Jun
@MinJun____
Followers
210
Following
584
Media
4
Statuses
195
Scientia Associate Professor and Program Lead, The George Institute for Global Health, Faculty of Medicine, UNSW Sydney; kidney epidemiology
Sydney, New South Wales
Joined May 2018
Dr Sradha Kotwal of @UNSW and @georgeinstitute has developed the Chronic Kidney Disease Adaptive Platform Trial Investigating Various Agents for Therapeutic Effect (CAPTIVATE), aiming to identify an effective drug to prevent CKD progression #KidneyHealthForAll #WorldKidneyDay
0
4
11
Come work with us! We have an exciting opening for a biostatistician to join the @georgeinstitute's Renal & Metabolic Division Great opportunity to work on large-scale cardiorenal randomised trials and routinely collected data https://t.co/PNSKoJvT2L DM me for details
0
5
13
"I wanted to look into an area of research that had the biggest impact on society." Hear more from Nelson about his work on cardiovascular prevention and his long-term goals for his future work via @heartfoundation:
0
1
1
Kidney Function, Albuminuria and Risk of Incident Atrial Fibrillation: A Systematic Review and Meta-Analysis https://t.co/s6g9BN3LuL
@_jeffreyha @DearbhlaKelly4 @brendonneuen @VladoPerkovic @MinJun____ @badves @georgeinstitute @UNSWMedicine #VisualAbstract
0
11
11
The Prevalence of #ChronicKidneyDisease in Australian #PrimaryCare: Analysis of a National General Practice Dataset #VisualAbstract by @jmteakell
https://t.co/F3YfR4nGz9
@MinJun____ @brendonneuen @SradhaKotwal @Badves @davidpeiris @jardine_meg @VladoPerkovic @georgeinstitute
0
4
12
Improved uptake of SGLT2i in people with CKD has the potential to substantially reduce the incidence of kidney failure in Australia Implementation now critical to realising these population level benefits Our new paper #openaccess in @LancetRH_WPac
https://t.co/PsOzzMJXyi
2
30
81
Latest granular data on CKD trends in Australia CKD is common & increasing year on year UACR testing remains abysmally low Major opportunities for early detection & treatment to prevent cardiovascular & kidney disease Led by @MinJun____ in @KIReports: https://t.co/hmW4k8tlYm
2
10
47
#ICYMI, check out this #ICESKDT study by @_jeffreyha and team that focused on determining the benefit–risk profile of rivaroxaban versus warfarin for atrial fibrillation in patients with #CKD. https://t.co/Jpmc9qGMMR
@ICESOntario @MinJun____ 1/
pubmed.ncbi.nlm.nih.gov
This real-world study involved a large cohort of 55,568 adults with atrial fibrillation from 5 jurisdictions across Australia and Canada. It showed that the favorable safety (bleeding) and effectiv...
1
7
12
Congratulations to @SradhaKotwal for securing @nhmrc funding to test new treatments in people with #ChronicKidneyDisease at trial centres in Australia & other countries. 🔗 https://t.co/V1ccX02XVL
2
9
27
The largest & most comprehensive analysis of the association between SGLT2i, blood pressure variability & cardiorenal outcomes While SGLT2i reduce BP, they have little to no effect on BP variability New #openaccess in @JAHA_AHA led by @Fletcher_RA
https://t.co/4ausKnVKi3
2
25
63
Sharing this real-world study 🇦🇺🇨🇦showing favorable⚖️ safety🩸& effectiveness of Riva vs Warfarin across broad range of kidney fn with some imp safety data in those with greatly ⏬ kidney fn @MinJun____ @georgeinstitute @UNSWMedicine
Safety and Effectiveness of Rivaroxaban Versus Warfarin Across GFR Levels in Atrial Fibrillation: A Population-Based Study in Australia 🇦🇺 and Canada 🇨🇦. @KidneyMed ➡️ https://t.co/hem8M8ONIN
0
4
8
Safety and Effectiveness of Rivaroxaban Versus Warfarin Across GFR Levels in Atrial Fibrillation: A Population-Based Study in Australia 🇦🇺 and Canada 🇨🇦. @KidneyMed ➡️ https://t.co/hem8M8ONIN
0
7
11
Congratulations to Drs Majed Al Jeraisy, Mohammed Tawhari and @Ahmed_Shaman from @kaimrc_ksa for enrolling their FIRST three patients in TRACK. We welcome Saudi Arabia 🇸🇦 to the TRACK trial.
2
4
14
Do multifaceted interventions or care bundles reduce #Dialysis catheter related bloodstream infections? Our researchers @SradhaKotwal and team have published ✍️imp new findings from their @reducction trial today in the @bmj_latest: ▶️ https://t.co/RVN1JuUAAG
0
11
19
@reducction @SradhaKotwal @dialysisbloke @sarah_scoggan @NephMcDonald @georgeinstitute Also provides impt insights into the scale of Hawthorne effect in such evidence implementation studies
0
1
3
Our studies found that as many as 434 million people across Asia could have chronic kidney disease and that it affects women and men differently. Urgent action in Asia is needed to prevent and manage CKD, including equitable policies that address the needs of both women and men
Millions of people with #ChronicKidneyDisease die annually because they cannot afford treatment. New research builds a clearer picture of the growing rates of #KidneyDisease in Asia & how it affects women & men differently. #WorldKidneyDay2022 🔗Read more https://t.co/uspECvxWWQ
0
4
6
Fantastic opportunity to work on practice changing trials and big data with collaborative colleagues, and to make a global impact - join us!! @GLDiTanna @MinJun____ @ArnottClare @SradhaKotwal @Badves @alta_schutte
Expressions of Interest invited from biostatisticians across all levels of experience to join our growing Biostatistics team! Check out details: https://t.co/vxAamZFlTY and connect with @GLDiTanna!
0
2
7
Congratulations to Sradha Kotwal, winner of the KIDNEY HEALTH AUSTRALIA (KHA) CLINICAL SCIENCE AWARD #ANZSNASM @SradhaKotwal @KidneyHealth @KarenDwyer12
2
7
18
Congratulations @drmanishasahay for randomising the 100th patient in @TRACK_trial Top recruiters are Hospital Tuanku Ja'afar, Seremban Hospital Raja Permaisuri Bainun, Ipoh Hospital Canselor Tuanku Muhriz Hospital Kajang University of Malaysia Medical Centre 1/3
2
3
12